nodes	percent_of_prediction	percent_of_DWPC	metapath
Phenylpropanolamine—SLC6A3—Gilles de la Tourette syndrome	0.854	1	CbGaD
Phenylpropanolamine—MAOA—Clearance of dopamine—SLC6A3—Gilles de la Tourette syndrome	0.00892	0.0803	CbGpPWpGaD
Phenylpropanolamine—MAOA—Biogenic Amine Synthesis—HDC—Gilles de la Tourette syndrome	0.00707	0.0637	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—autonomic nervous system—Gilles de la Tourette syndrome	0.00693	0.234	CbGeAlD
Phenylpropanolamine—DRD1—Dopamine receptors—DRD3—Gilles de la Tourette syndrome	0.00637	0.0573	CbGpPWpGaD
Phenylpropanolamine—DRD1—Dopamine receptors—DRD4—Gilles de la Tourette syndrome	0.00618	0.0557	CbGpPWpGaD
Phenylpropanolamine—DRD1—Dopamine receptors—DRD2—Gilles de la Tourette syndrome	0.00576	0.0518	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neurotransmitter Clearance In The Synaptic Cleft—SLC6A3—Gilles de la Tourette syndrome	0.00407	0.0366	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Na+/Cl- dependent neurotransmitter transporters—SLC6A3—Gilles de la Tourette syndrome	0.00214	0.0192	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00165	0.0149	CbGpPWpGaD
Phenylpropanolamine—DRD1—midbrain—Gilles de la Tourette syndrome	0.00165	0.0556	CbGeAlD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00148	0.0134	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Amine compound SLC transporters—SLC6A3—Gilles de la Tourette syndrome	0.00148	0.0134	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00145	0.0131	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Monoamine Transport—SLC6A3—Gilles de la Tourette syndrome	0.00141	0.0127	CbGpPWpGaD
Phenylpropanolamine—DRD1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00141	0.0127	CbGpPWpGaD
Phenylpropanolamine—DRD1—Hypothetical Network for Drug Addiction—DRD4—Gilles de la Tourette syndrome	0.0014	0.0126	CbGpPWpGaD
Phenylpropanolamine—DRD1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00137	0.0123	CbGpPWpGaD
Phenylpropanolamine—DRD1—nervous system—Gilles de la Tourette syndrome	0.00135	0.0457	CbGeAlD
Phenylpropanolamine—SLC6A3—midbrain—Gilles de la Tourette syndrome	0.00132	0.0446	CbGeAlD
Phenylpropanolamine—DRD1—Hypothetical Network for Drug Addiction—DRD2—Gilles de la Tourette syndrome	0.0013	0.0117	CbGpPWpGaD
Phenylpropanolamine—DRD1—central nervous system—Gilles de la Tourette syndrome	0.0013	0.044	CbGeAlD
Phenylpropanolamine—DRD1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00127	0.0115	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00127	0.0114	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00124	0.0111	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.00123	0.0111	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.0012	0.0108	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.0012	0.0108	CbGpPWpGaD
Phenylpropanolamine—DRD1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00118	0.0106	CbGpPWpGaD
Phenylpropanolamine—DRD1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00115	0.0103	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00114	0.0103	CbGpPWpGaD
Phenylpropanolamine—Phentermine—SLC6A3—Gilles de la Tourette syndrome	0.00114	0.202	CrCbGaD
Phenylpropanolamine—ADRB2—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00112	0.0101	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—GPR63—Gilles de la Tourette syndrome	0.00112	0.01	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—nervous system—Gilles de la Tourette syndrome	0.00109	0.0367	CbGeAlD
Phenylpropanolamine—Dextroamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.00109	0.193	CrCbGaD
Phenylpropanolamine—Pseudoephedrine—SLC6A3—Gilles de la Tourette syndrome	0.00108	0.191	CrCbGaD
Phenylpropanolamine—DRD1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.00107	0.00963	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00106	0.00957	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—central nervous system—Gilles de la Tourette syndrome	0.00105	0.0353	CbGeAlD
Phenylpropanolamine—ADRB2—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00104	0.00936	CbGpPWpGaD
Phenylpropanolamine—DRD1—brain—Gilles de la Tourette syndrome	0.00103	0.0349	CbGeAlD
Phenylpropanolamine—ADRB1—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00103	0.00929	CbGpPWpGaD
Phenylpropanolamine—ADRB1—nervous system—Gilles de la Tourette syndrome	0.00103	0.0348	CbGeAlD
Phenylpropanolamine—ADRA1A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.00102	0.00922	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.00101	0.00909	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000994	0.00895	CbGpPWpGaD
Phenylpropanolamine—ADRB1—central nervous system—Gilles de la Tourette syndrome	0.000993	0.0335	CbGeAlD
Phenylpropanolamine—MAOA—midbrain—Gilles de la Tourette syndrome	0.000983	0.0332	CbGeAlD
Phenylpropanolamine—ADRB1—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000962	0.00866	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Monoamine GPCRs—DRD3—Gilles de la Tourette syndrome	0.000951	0.00856	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000941	0.00847	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.000926	0.00833	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Monoamine GPCRs—DRD4—Gilles de la Tourette syndrome	0.000923	0.00831	CbGpPWpGaD
Phenylpropanolamine—DRD1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000891	0.00802	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—nervous system—Gilles de la Tourette syndrome	0.000877	0.0296	CbGeAlD
Phenylpropanolamine—Amphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000875	0.155	CrCbGaD
Phenylpropanolamine—ADRA1A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.00086	0.00775	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Monoamine GPCRs—DRD2—Gilles de la Tourette syndrome	0.00086	0.00774	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—central nervous system—Gilles de la Tourette syndrome	0.000844	0.0285	CbGeAlD
Phenylpropanolamine—ADRA1A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000835	0.00752	CbGpPWpGaD
Phenylpropanolamine—SLC6A3—brain—Gilles de la Tourette syndrome	0.000831	0.0281	CbGeAlD
Phenylpropanolamine—ADRA1A—nervous system—Gilles de la Tourette syndrome	0.000815	0.0275	CbGeAlD
Phenylpropanolamine—Methamphetamine—SLC6A3—Gilles de la Tourette syndrome	0.000811	0.144	CrCbGaD
Phenylpropanolamine—MAOA—nervous system—Gilles de la Tourette syndrome	0.000808	0.0273	CbGeAlD
Phenylpropanolamine—ADRB1—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000801	0.00721	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Amine ligand-binding receptors—DRD3—Gilles de la Tourette syndrome	0.0008	0.0072	CbGpPWpGaD
Phenylpropanolamine—ADRB1—brain—Gilles de la Tourette syndrome	0.000788	0.0266	CbGeAlD
Phenylpropanolamine—ADRA1A—central nervous system—Gilles de la Tourette syndrome	0.000785	0.0265	CbGeAlD
Phenylpropanolamine—ADRB2—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000784	0.00706	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000778	0.00701	CbGpPWpGaD
Phenylpropanolamine—MAOA—central nervous system—Gilles de la Tourette syndrome	0.000778	0.0263	CbGeAlD
Phenylpropanolamine—ADRA2A—Amine ligand-binding receptors—DRD4—Gilles de la Tourette syndrome	0.000776	0.00699	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—midbrain—Gilles de la Tourette syndrome	0.000754	0.0255	CbGeAlD
Phenylpropanolamine—DRD1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000749	0.00675	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Amine ligand-binding receptors—DRD2—Gilles de la Tourette syndrome	0.000723	0.00651	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000674	0.00606	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—brain—Gilles de la Tourette syndrome	0.00067	0.0226	CbGeAlD
Phenylpropanolamine—ADRB2—Arf6 signaling events—MET—Gilles de la Tourette syndrome	0.000667	0.006	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000659	0.00593	CbGpPWpGaD
Phenylpropanolamine—Amphetamine—DRD2—Gilles de la Tourette syndrome	0.000651	0.115	CrCbGaD
Phenylpropanolamine—ADRA1A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000648	0.00584	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—brain—Gilles de la Tourette syndrome	0.000623	0.021	CbGeAlD
Phenylpropanolamine—ADRA2A—nervous system—Gilles de la Tourette syndrome	0.00062	0.0209	CbGeAlD
Phenylpropanolamine—MAOA—brain—Gilles de la Tourette syndrome	0.000618	0.0209	CbGeAlD
Phenylpropanolamine—ADRA2A—Monoamine GPCRs—HTR2A—Gilles de la Tourette syndrome	0.000602	0.00542	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—central nervous system—Gilles de la Tourette syndrome	0.000597	0.0202	CbGeAlD
Phenylpropanolamine—SLC6A2—Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds—SLC6A3—Gilles de la Tourette syndrome	0.00058	0.00522	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Other—DRD3—Gilles de la Tourette syndrome	0.00055	0.00495	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000545	0.00491	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Other—DRD4—Gilles de la Tourette syndrome	0.000534	0.0048	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Amine ligand-binding receptors—HTR2A—Gilles de la Tourette syndrome	0.000506	0.00456	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—brain—Gilles de la Tourette syndrome	0.000474	0.016	CbGeAlD
Phenylpropanolamine—SLC6A2—NRF2 pathway—SLC6A3—Gilles de la Tourette syndrome	0.000418	0.00377	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Other—HTR2A—Gilles de la Tourette syndrome	0.000348	0.00313	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—DRD3—Gilles de la Tourette syndrome	0.000332	0.00299	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—DRD4—Gilles de la Tourette syndrome	0.000322	0.0029	CbGpPWpGaD
Phenylpropanolamine—MAOA—Transmission across Chemical Synapses—SLC6A3—Gilles de la Tourette syndrome	0.00031	0.00279	CbGpPWpGaD
Phenylpropanolamine—DRD1—Circadian rythm related genes—DRD2—Gilles de la Tourette syndrome	0.0003	0.0027	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000272	0.00244	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000264	0.00237	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—SLC-mediated transmembrane transport—SLC6A3—Gilles de la Tourette syndrome	0.000264	0.00237	CbGpPWpGaD
Phenylpropanolamine—MAOA—SIDS Susceptibility Pathways—HTR2A—Gilles de la Tourette syndrome	0.00026	0.00234	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000246	0.00221	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000244	0.0022	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000239	0.00215	CbGpPWpGaD
Phenylpropanolamine—MAOA—Neuronal System—SLC6A3—Gilles de la Tourette syndrome	0.000237	0.00214	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000237	0.00213	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000233	0.00209	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000232	0.00209	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000226	0.00203	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000221	0.00199	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000216	0.00194	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.00021	0.00189	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000209	0.00188	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000205	0.00184	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000203	0.00183	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000199	0.00179	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—DRD3—Gilles de la Tourette syndrome	0.000198	0.00178	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000198	0.00178	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—DRD4—Gilles de la Tourette syndrome	0.000192	0.00173	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000192	0.00173	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000189	0.0017	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000185	0.00167	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD3—Gilles de la Tourette syndrome	0.000184	0.00165	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—G alpha (i) signalling events—DRD2—Gilles de la Tourette syndrome	0.000179	0.00161	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000179	0.00161	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD4—Gilles de la Tourette syndrome	0.000178	0.0016	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000177	0.0016	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000172	0.00155	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000172	0.00155	CbGpPWpGaD
Phenylpropanolamine—MAOA—Metabolism—HDC—Gilles de la Tourette syndrome	0.000172	0.00155	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000169	0.00152	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—DRD2—Gilles de la Tourette syndrome	0.000166	0.00149	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000164	0.00148	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—G alpha (q) signalling events—HTR2A—Gilles de la Tourette syndrome	0.000162	0.00146	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.00016	0.00144	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000159	0.00143	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD3—Gilles de la Tourette syndrome	0.000157	0.00142	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000156	0.0014	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000155	0.00139	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000155	0.00139	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000153	0.00138	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD4—Gilles de la Tourette syndrome	0.000153	0.00137	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000151	0.00136	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000151	0.00136	CbGpPWpGaD
Phenylpropanolamine—DRD1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000147	0.00133	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—Gilles de la Tourette syndrome	0.000145	0.0013	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000144	0.0013	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—DRD2—Gilles de la Tourette syndrome	0.000142	0.00128	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000141	0.00127	CbGpPWpGaD
Phenylpropanolamine—SLC6A2—Transmembrane transport of small molecules—SLC6A3—Gilles de la Tourette syndrome	0.000134	0.00121	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000132	0.00119	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.00013	0.00117	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.000129	0.00116	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000125	0.00113	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000125	0.00113	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD3—Gilles de la Tourette syndrome	0.00012	0.00108	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000117	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCRs, Class A Rhodopsin-like—HTR2A—Gilles de la Tourette syndrome	0.000116	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD4—Gilles de la Tourette syndrome	0.000116	0.00105	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Metabolism—HDC—Gilles de la Tourette syndrome	0.000115	0.00103	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000112	0.00101	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—DRD2—Gilles de la Tourette syndrome	0.000108	0.000975	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	0.000107	0.000965	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	0.000101	0.000908	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	0.0001	0.000901	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—HTR2A—Gilles de la Tourette syndrome	9.96e-05	0.000897	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	9.87e-05	0.000888	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	9.72e-05	0.000875	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	9.09e-05	0.000819	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	9.06e-05	0.000815	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	9e-05	0.00081	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	8.83e-05	0.000795	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	8.81e-05	0.000793	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.74e-05	0.000787	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	8.55e-05	0.00077	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	8.22e-05	0.00074	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	8.17e-05	0.000736	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	8.16e-05	0.000735	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	8.14e-05	0.000733	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	8e-05	0.00072	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	7.96e-05	0.000717	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.94e-05	0.000714	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	7.76e-05	0.000699	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR ligand binding—HTR2A—Gilles de la Tourette syndrome	7.59e-05	0.000683	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.39e-05	0.000666	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	7.28e-05	0.000656	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	7.23e-05	0.000651	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	7.07e-05	0.000637	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD3—Gilles de la Tourette syndrome	6.77e-05	0.000609	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.61e-05	0.000595	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.59e-05	0.000593	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD4—Gilles de la Tourette syndrome	6.57e-05	0.000591	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	6.42e-05	0.000578	CbGpPWpGaD
Phenylpropanolamine—DRD1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	6.34e-05	0.000571	CbGpPWpGaD
Phenylpropanolamine—CYP1A2—Metabolism—HDC—Gilles de la Tourette syndrome	6.34e-05	0.000571	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD3—Gilles de la Tourette syndrome	6.15e-05	0.000553	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—DRD2—Gilles de la Tourette syndrome	6.12e-05	0.000551	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.98e-05	0.000538	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD4—Gilles de la Tourette syndrome	5.97e-05	0.000537	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.76e-05	0.000518	CbGpPWpGaD
Phenylpropanolamine—ADRB1—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.7e-05	0.000513	CbGpPWpGaD
Phenylpropanolamine—ADRB2—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	5.58e-05	0.000502	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—DRD2—Gilles de la Tourette syndrome	5.56e-05	0.0005	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	5.37e-05	0.000484	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	5.21e-05	0.000469	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.18e-05	0.000466	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	5.07e-05	0.000456	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.86e-05	0.000437	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.83e-05	0.000435	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	4.72e-05	0.000425	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.69e-05	0.000422	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.61e-05	0.000415	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	4.59e-05	0.000413	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.37e-05	0.000393	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—GPCR downstream signaling—HTR2A—Gilles de la Tourette syndrome	4.29e-05	0.000386	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	4.27e-05	0.000385	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	4.19e-05	0.000377	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.91e-05	0.000352	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling by GPCR—HTR2A—Gilles de la Tourette syndrome	3.89e-05	0.00035	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.79e-05	0.000341	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD3—Gilles de la Tourette syndrome	3.63e-05	0.000327	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.53e-05	0.000318	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD4—Gilles de la Tourette syndrome	3.52e-05	0.000317	CbGpPWpGaD
Phenylpropanolamine—DRD1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.4e-05	0.000306	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—DRD2—Gilles de la Tourette syndrome	3.28e-05	0.000296	CbGpPWpGaD
Phenylpropanolamine—ADRB1—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	3.06e-05	0.000275	CbGpPWpGaD
Phenylpropanolamine—ADRB2—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.99e-05	0.000269	CbGpPWpGaD
Phenylpropanolamine—ADRA1A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.47e-05	0.000223	CbGpPWpGaD
Phenylpropanolamine—ADRA2A—Signaling Pathways—HTR2A—Gilles de la Tourette syndrome	2.3e-05	0.000207	CbGpPWpGaD
